Dazodalibep for Sjögren’s Disease

Dazodalibep is currently in phase 3 clinical trials.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. St. Clair EW, Alecios I, Rees W, et al. Dazodalibep (VIB4920/HZN4920) in Sjögren’s subjects with an unacceptable symptom burden: Safety and efficacy from a phase 2, randomized, double-blind study [abstract LB0003]. Ann Rheum Dis. 2023;82:201.
2. Sandoval-Flores MG, Chan-Campos I, Hernández-Molina G. Factors influencing the EULAR Sjögren’s Syndrome Patient-Reported Index in primary Sjögren’s syndrome. Clin Exp Rheumatol. 2021 Nov–Dec;39 Suppl 133(6):153–158.
3. American College of Rheumatology. Disease & conditions: Sjögren’s disease. Updated 2025 Feb. https://tinyurl.com/ydwn5crr.
4. A study to evaluate the efficacy and safety of VIB4920 in participants with Sjögren’s syndrome (SS) [NCT04129164]. Amgen. ClinicalTrials.gov. 2023 March 10.
5. American Academy of Ophthalmology. EyeWiki: Dry eye syndrome questionnaires. 2023 Mar 12. https://tinyurl.com/4bskz7pa.
6. St. Clair EW, Wang L, Alevizos I, et al. Efficacy and safety of dazodalibep (VIB4920/HZN4920) in subjects with Sjögren’s sydrome: A phase 2, randomized, double-blind, placebo-controlled, proof of concept study [abstract OP0143]. Ann Rheum Dis. 2023;82:201. https://tinyurl.com/7v965zu8.

Adapted from an article in the November 2023 issue of The Rheumatologist (Vol. 17, No. 11).